and this was an idea that i stole from someone much smarter than myself, peter bach, from memorial sloan kettering. peter's been talking about this for a long time. what it essentially does is it recognizes that a drug is initially brought to the marketplace for one indication. let's take tarciva in lung cancer. it's a lung cancer agent. for the right patient, it can extend life by 5.2 months. for pancreatic cancer, it will extend your life for 12 days. now, the trouble for us as consumers is do you ever pay the exact same amount for something that works one tenth as well? name another product that would work as one-tenth as well you would pay the same market price. in our marketplace, that's what we see. what we've done to make this happen in 2016, we had to do three things. one, we had to change our systems so that we could actually adjudicate drugs at the indication level and not just the drug level. because right now, all claims are at the drug level. but we have got to get the information on the indication that it's going to be used for. the second thing we needed is we needed etern